Navigation Links
HIV Vaccine Trials Network Opens Enrollment for Phase 1 Trial of GeoVax Labs' Second Generation HIV Vaccine
Date:5/22/2012

f the U.S. National Institutes of Health (NIH).

Robert McNally, Ph.D, President and Chief Executive Officer of GeoVax, said, "We are extremely pleased the HVTN is conducting the trial with the adjuvanted vaccine. They have substantial experience with our unadjuvanted vaccine and possess appropriate expertise for this first human trial of our GM-CSF co-expressing vaccine that has shown such good promise in preclinical studies."

About GeoVax
GeoVax Labs, Inc. is a biotechnology company developing human vaccines for HIV (Human Immunodeficiency Virus – that leads to AIDS). GeoVax's HIV/AIDS vaccine technology is exclusively licensed from Emory University in Atlanta, GA, and is the subject of more than 20 issued or filed patent applications. GeoVax vaccines are designed for use in uninfected people to prevent acquisition of HIV-1 and limit the progression to AIDS should a person become infected. GeoVax vaccines are also being tested as a therapeutic treatment (for people already infected with the HIV-1 virus).

GeoVax's core vaccine technologies were developed by Dr. Harriet Robinson, Chief Scientific Officer, through a collaboration of colleagues at Emory University's Vaccine Center, the National Institute of Allergy and Infectious Diseases (NIAID), the Centers for Disease Control and Prevention (CDC) and GeoVax. The technology uses recombinant DNA to prime the immune response and recombinant modified vaccinia Ankara (MVA) to boost the primed response.  Both the DNA vaccine and the MVA vaccine express non-infectious virus-like-particles displaying the natural trimeric form of the HIV envelope protein.

GeoVax's vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. These trials have tested various combinations and doses of the DNA and MVA vaccines, their ability to raise anti-HIV humoral (antibody) and cellular (cytotoxic T cell) immune
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
4. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
5. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
6. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
7. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
8. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
9. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
10. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
11. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... , May 22, 2013 STEPh, Inc., a ... the launch of their web site ( http://www.stephreports.com ... About STEPh Reports STEPh ... Each STEPh Report assesses the competitive ... projected launch year, company, and specific key issues.  STEPh ...
(Date:5/22/2013)... May 22, 2013   Upsher-Smith Laboratories, ... of its global Phase III clinical trial ... program for the management of epilepsy in ... USL255 is specifically engineered to provide convenient ... blood levels observed with currently available treatment ...
(Date:5/22/2013)... N.J. , May 22, 2013 MEDIFIRST ... opportunity to update shareholders about some recent company developments. ... expand its avenues of communication with shareholders. Integrating social ... launched a Facebook page and will post updates on ... Twitter hashtag is #medifirstusa. Says CEO ...
Breaking Medicine Technology:Scientific and Technical Evaluation of Pharmaceuticals, Inc. [STEPh, Inc.], Launches New Competitive Intelligence Web Site 2Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 2Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 3Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 4Medifirst Solutions, Inc. Announces Update To Shareholders 2
... , NEWARK, Del. and GRONINGEN, Netherlands ... a leading full-service GLP/GCP-compliant contract research organization providing testing ... announced the completion of its acquisition of Xendo Drug ... .  XDD, a European contract research organization (CRO), will ...
... TEMPE, Ariz. , July 26 Harco Metal ... seamless, cost effective manufacturing, announced today the contract to manufacture MediGLIDER™ ... , ... created the MediGLIDER™ to address the growing risk and cost associated ...
Cached Medicine Technology:QPS Announces the Acquisition of Xendo Drug Development 2QPS Announces the Acquisition of Xendo Drug Development 3QPS Announces the Acquisition of Xendo Drug Development 4Harco Partners With ConMediSys to Deliver Patient Safety and Equipment Integrity 2
(Date:5/22/2013)... 2013 The Muscular Dystrophy Association scored ... at the annual Charlotte Muscle Team event held May ... families living with muscle disease. , "The Charlotte ... support MDA families,” said MDA Divisional Director Theresa Miller. ... with a "Buddy" to make their night extra special, ...
(Date:5/22/2013)... Dennis Thompson HealthDay Reporter , , WEDNESDAY, May ... or back pain are more likely to attempt suicide, ... another psychiatric condition, according to a new study. ... should be aware they are at increased risk of ... Affairs Serious Mental Illness Treatment Resource and Evaluation Center ...
(Date:5/22/2013)... 22, 2013 Diversity Focus and Handicap ... The performance promotes awareness that physical disabilities do ... This! performance will be held Friday, June 14th at ... Tickets for Handicap This! can be purchased at ... measure the level to which their mind is handicap ...
(Date:5/22/2013)... in genomic health disparities from the University of Miami ... of Medicine have teamed up to hold the second ... Disparities in Genomic Medicine." The theme of this ... and government to reduce these disparities. , Despite steady ... individuals within underserved groups continue to be more vulnerable ...
(Date:5/22/2013)... York (PRWEB) May 22, 2013 Phelps ... established the Westchester Lung Nodule Center for individuals ... receive lung cancer care. Lung cancer is the deadliest form ... more people in the U.S. die from lung cancer than ... with all cancers, early detection increases survival rates. It ...
Breaking Medicine News(10 mins):Health News:Charlotte Muscle Team Event Raises $300,000 in the Fight Against Muscle Disease 2Health News:Migraine, Chronic Back Pain Tied to Higher Suicide Risk 2Health News:Migraine, Chronic Back Pain Tied to Higher Suicide Risk 3Health News:Handicap This! Comes to Marion, Iowa 2Health News:Why We Can't Wait: Conference to Eliminate Health Disparities in Genomic Medicine 2Health News:Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care 2Health News:Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care 3
... 4,000 people in the UK die each year from the effects of asbestos ... ... November 1999, the Government,s ban on the use of Asbestos came into force. ... die each year from the effects of asbestos exposure whilst at work. ...
... The Committee for Human,Medicinal Products (CHMP) ... once-daily dosing of 800 mg PREZISTA(R) (darunavir) ... in treatment-naive adults (those who,have never taken ... was,developed by Tibotec Pharmaceuticals, and Tibotec, a ...
... growth, experts say , , THURSDAY, Nov. 27 (HealthDay ... on your plate this Thanksgiving, because it may help protect ... Urological Association. , The high acid content in cranberries, ... simple UTIs, help inhibit bacterial growth along the urinary tract, ...
... 27 /PRNewswire-Asia-FirstCall/ -- China,s leading,integrated medical device and ... or "the Company", Stock Code: 8180.HK) is,pleased to ... in,Atlantis Investment Management Limited ("Atlantis Investment") as financial,investors ... shares at a price,HK$1.03 per share. , ...
... To coincide with Staying Alive,s tenth,anniversary on World AIDS ... of Travis McCoy, lead vocalist of the alternative,hip-hop band ... , Travis joins ... Beyonce, Mary J Blige, Justin Timberlake and Diddy, who ...
... healthcare services for seasonal vineyard workers and their families. In ... 2007 vintage. , ... Portland, OR (PRWEB) November 26, ... contributed generously to the 17th annual benefit with animated bidding on ...
Cached Medicine News:Health News:Nine Year Ban Fails to Eradicate Asbestos Related Diseases 2Health News:Nine Year Ban Fails to Eradicate Asbestos Related Diseases 3Health News:European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion for Once-Daily PREZISTA(R) (Darunavir) as Part of Combination Therapy for Treatment-Naive Adults With HIV-1 2Health News:European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion for Once-Daily PREZISTA(R) (Darunavir) as Part of Combination Therapy for Treatment-Naive Adults With HIV-1 3Health News:European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion for Once-Daily PREZISTA(R) (Darunavir) as Part of Combination Therapy for Treatment-Naive Adults With HIV-1 4Health News:Cranberries May Help Prevent Urinary Tract Infections 2Health News:Golden Meditech Brings in Financial Investor Through New Share Issuance 2Health News:On Staying Alive's 10th Anniversary, Gym Class Heroes Singer Travis McCoy Named 2009 Foundation Ambassador 2Health News:On Staying Alive's 10th Anniversary, Gym Class Heroes Singer Travis McCoy Named 2009 Foundation Ambassador 3Health News:On Staying Alive's 10th Anniversary, Gym Class Heroes Singer Travis McCoy Named 2009 Foundation Ambassador 4Health News:On Staying Alive's 10th Anniversary, Gym Class Heroes Singer Travis McCoy Named 2009 Foundation Ambassador 5Health News:On Staying Alive's 10th Anniversary, Gym Class Heroes Singer Travis McCoy Named 2009 Foundation Ambassador 6Health News:Despite Economy, Oregon Wine Benefit !Salud! Raises Over $735,000 2Health News:Despite Economy, Oregon Wine Benefit !Salud! Raises Over $735,000 3
... Anchor allows one step fixation of soft tissue ... knotless rotator cuff repair in one simple insertion ... thread diameter of 5 mm and a small ... sutures securely hold a thin, bioabsorbable PLLA disc ...
... a 3 mm bioabsorbable push-in suture anchor with ... attachment to bone in the shoulder joint and ... high pull-out strength is required. The exclusive braided ... of the anchor and provides superior resistance to ...
TigerStick is a white #2 FiberStick with black stripes and a stiffened, 12 inch, waxed end. It is especially useful when motion determination and alternating colored sutures are required in the arthr...
... the Flowmaster. It is a new portable digital ... ease of use, simplicity and cost effectiveness are ... it now very easy to give a patient ... want and data will be send wirelessly to ...
Medicine Products: